Company ProfilePremium

HRL Holdings Limited

Company Profile Analysis

Ticker: HRL.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
HRL Holdings Limited - Company showcase

Year Founded & Workforce

2006

HRL Holdings Limited logo

HRL Holdings Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

HRL Holdings Limited Overview

HRL Holdings was a Brisbane-headquartered micro-cap that converted itself from a failed geothermal explorer (Hot Rock Limited) into a specialist testing, inspection and data-management group serving Australia and New Zealand. Its rebuild started with the 2014 purchase of Octief, a Queensland asbestos and hazardous-materials consultancy. It continued with the 2014–15 purchase of Precise Consulting, a New Zealand hazardous-materials testing laboratory. The decisive step was the November 2017 acquisition of Analytica Laboratories in Hamilton, New Zealand. Analytica was a niche chemistry laboratory with leading positions in mānuka honey authentication and dairy/raw-milk testing, and it roughly doubled group revenue. Around this core, HRL built a hazmat consulting arm, a Queensland geotechnical testing unit and the Octfolio cloud software platform. By FY2021 revenue was A$34.6m and underlying EBITDA was A$7.7m. HRL's niche laboratory franchise attracted ALS Limited, which bought it in 2022 for about A$82m to deepen its ANZ food and environmental testing footprint.


What the company did

HRL Holdings was a diversified environmental and laboratory services provider operating offices and laboratories across Australia and New Zealand. ALS's acquisition announcement (6 September 2022) described HRL as a provider of sampling, laboratory testing and data-management capabilities for the food, environmental and occupational hygiene industries. McCullough Robertson, HRL's legal adviser on the takeover, summarised HRL as specialising in integrated field sampling, laboratory analysis and cloud-hosted asset management.

Third-party company profiles based on HRL's annual reports list four operating segments:

  1. HAZMAT services: asbestos and hazardous-materials management, property contamination testing, workplace drug testing, environmental testing, on-site testing and monitoring.

  2. Food and Environmental Laboratory services: honey testing, milk and dairy testing, food-origin testing, drugs-of-abuse laboratory testing, asbestos laboratory analysis, environmental laboratory testing, and other laboratory R&D services.

  3. Geotechnical services: geotechnical investigation and study, temporary works design and inspection, construction-phase verification, earthworks supervision, soil/concrete/aggregate testing, and on-site mobile laboratory testing.

  4. Software services: information-management software for asbestos and hazardous materials, field-management software, and customised workplace health and safety compliance applications (Octfolio).

The Food and Environmental Laboratory segment generated the largest share of revenue, and New Zealand was the majority geographic source of revenue (moomoo company profile, derived from HRL annual reports).

Business model and revenue model

Revenue model componentCharacterisationEvidence
Fee-for-test laboratory services (per sample)Dominant revenue model; transactional and recurring through regulatory and export-certification programmesAnalytica honey, dairy, food-origin and environmental testing
Consulting / field services (time-and-materials, project fees)Hazmat surveys, asbestos management plans, air monitoring, contamination assessmentsOctief (Australia), Precise Consulting (NZ)
Construction materials testing (project-based)Earthworks supervision, soil/concrete/aggregate testing tied to Queensland civil constructionGeotechnical segment
Software (subscription / SaaS licensing)Cloud-hosted asbestos registers and hazmat data platformOctfolio
Product sales / licensing of IPNot a material disclosed revenue line—

The exact revenue mix split between service, consulting and subscription revenue was not publicly disclosed beyond segment level.

Value-chain position

HRL sat in the testing, inspection and certification (TIC) value chain as an independent third-party laboratory and field-sampling provider. Its "integrated" model, which it marketed throughout its listed life, combined three steps: field sampling by consultants (Octief/Precise), laboratory analysis (Analytica and in-house asbestos laboratories), and data delivery through a cloud platform (Octfolio). The aim was to capture more of each client's compliance spend than a pure laboratory or pure consultancy could.

Customer types and end-markets

End-marketCustomer typesKey services
Food and agri-exports (NZ)Honey producers and exporters, dairy processors, raw-milk suppliers, infant-formula exportersMānuka honey authentication, glyphosate and AFB (American foulbrood) testing, raw milk testing, export certification support via CAIQTest Pacific
Occupational hygiene / built environmentBuilding owners, government asset owners, property managers, construction contractorsAsbestos surveys, air monitoring, hazardous materials registers
Residential property (NZ)Landlords, housing agencies, property managersMethamphetamine residue testing (a material line until the 2018 market collapse)
Civil construction (QLD)Contractors, engineering firms, infrastructure ownersGeotechnical testing, earthworks supervision, materials testing
EnvironmentalCouncils, consultancies, industrial clientsWater testing (expanded via Water Testing Hawke's Bay), soil contamination

Company's own description vs independent characterisation

Company/acquirer description (paraphrased from the ALS release, Sep 2022): an industry-leading provider of sampling, testing and data management for food, environmental and occupational hygiene markets, with Analytica described as an industry leader in honey and dairy testing and Octfolio as a fully integrated asbestos testing and data platform.

Independent characterisation: HRL was a sub-scale roll-up with one genuinely advantaged asset. Analytica's specialist chemistry franchise in NZ honey and dairy produced the bulk of group earnings: Taylor Collison estimated core lab testing at about 80% of group earnings in 1H FY21, with 28% EBITDA margins. Around it sat lower-margin, more cyclical consulting and construction-testing units. The hazmat arm was profitable but competitive. Geotechnical was a persistent laggard. Octfolio was strategically interesting but small. The equity story therefore came down to Analytica's growth runway versus the drag from the rest. That structure explains why a strategic buyer (ALS) could pay a 95% premium and still acquire the business at a modest multiple of group EBITDA.

Strategy

HRL's stated strategy (listed era, paraphrased from investor materials and management commentary)

  1. Niche chemical testing: target specialist, defensible testing niches rather than commodity volume testing. CEO Dabelstein framed Analytica as consistent with a strategy of targeting niche chemical testing (2017).

  2. Integrated sampling–lab–data model: link field consultants, laboratories and the Octfolio platform to capture the full compliance workflow.

  3. Transfer Analytica capability to Australia: management said it saw the opportunity to bring Analytica's testing capability from New Zealand to Australia.

  4. Acquisitive growth: pursue value-accretive acquisitions, including entry into NSW and Victoria (2018 investor presentation, via Strawman), "bolt-on" testing lines such as Water Testing Hawke's Bay (2021), and potentially a larger transformational deal (NovaPort, 2021).

  5. Stable, regulated markets: an emphasis on stable markets, customer intimacy and share gains (Taylor Collison summary of management positioning, 2021).

Initiatives in the final 24 months of independence (mid-2020 to mid-2022)

InitiativeTimingDetail
Honey testing line extensionsFY2020–FY2021Glyphosate and AFB testing to offset normalising mānuka volumes
Raw milk and dairy share gainsFY2020–FY2021Target of the broader NZ milk product testing market (about NZ$40m per Taylor Collison)
CAIQTest Pacific growthFY2021Revenue up 36%; export certification support
Water Testing Hawke's Bay acquisition2,021Expanded environmental/water testing lines in NZ
Geotechnical baseline contracts2,021Secured baseline volume work for the laggard geotechnical arm (NovaPort)
Octfolio software developmentOngoingRecognised by investors as an under-monetised opportunity
Capex programmeFY2022About A$4m guided

Sustainability and ESG commitments and formal cost-out programmes with targets: not publicly disclosed.

Guidance history

PeriodGuidanceOutcome
FY2019 (Nov 2018 AGM)A$2.2–2.5m adverse EBITDA impact from meth screeningDelivered a materially lower FY2019
1H FY2021EBITDA A$3.2–3.5mA$3.535m, at top end
FY2022Capex about A$4mNot reported (company acquired)

Strategy after the acquisition (as part of ALS)

ALS's stated rationale was to strengthen its Life Sciences operations with complementary food and environmental capabilities. It expected regulation and safety and quality-assurance programmes to keep driving ANZ food and environmental testing demand (ALS release, 6 Sep 2022). The visible integration steps are the rebranding of Octief to ALS Environmental Risk Services and the retention of Octfolio as ALS's hazmat data platform, which together show the "sampling + lab + digital" model being absorbed into ALS.

Products & Services

Food and Environmental Laboratory Services (Analytica Laboratories, Hamilton NZ)

OfferingDescriptionTarget customerNotes
Mānuka honey authentication testingChemical and DNA marker testing to verify mānuka honey under NZ Ministry for Primary Industries (MPI) definitionsNZ honey producers and exportersAnalytica described by ALS as an industry leader in honey testing; volumes highly seasonal (bumper FY2020 season)
Honey residue testing (glyphosate)Detection of glyphosate residues in honey for export market complianceHoney exportersGrowth line cited by Taylor Collison in FY2021
AFB (American foulbrood) testingTesting for bacterial bee diseaseBeekeepers, apiary regulatorsGrowth line cited by Taylor Collison in FY2021
Milk and dairy testingRaw milk and dairy product compositional and quality testingDairy processors, raw-milk suppliersHRL captured raw-milk share; Taylor Collison saw a broader NZ milk product testing market of about NZ$40m as an opportunity
Infant formula / export certification supportTesting supporting China-bound infant formula exports via CAIQTest PacificInfant formula exportersAnalytica part-owned CAIQTest Pacific (Stockhead, 2017)
Food origin testingIsotopic/chemical testing to verify geographic originFood exporters, brand ownersListed in company service profile
Drugs-of-abuse laboratory testingLaboratory analysis for workplace and residential drug testing, including methamphetamine residueEmployers, property managers, housing agenciesVolumes collapsed in NZ in 2018
Asbestos laboratory analysisIdentification of asbestos in bulk, soil and air samplesHazmat consultants (internal and external)Supports Octief/Precise field work
Environmental laboratory testingSoil, water and environmental chemistry testingCouncils, consultants, industrial clientsExpanded by Water Testing Hawke's Bay (2021)
Laboratory R&D servicesContract method development and researchIndustry clientsPricing not publicly disclosed

HAZMAT Services (Octief — Australia; Precise Consulting — NZ)

OfferingDescriptionTarget customer
Asbestos surveys and auditsInspection, sampling and identification of asbestos-containing materialsBuilding owners, government, schools, contractors
Asbestos management plans and registersCompliance documentation under Australian WHS regulationsAsset owners, facility managers
Air monitoring / clearance inspectionsAir sampling during and after asbestos removalRemovalists, principal contractors
Lead, mould and silica testingHazardous material identification (in-house lab offers asbestos, mould and silica analysis per ALS ERS page)Property owners, employers
Property contamination testingSoil and building contamination assessmentsProperty developers, owners
Workplace drug testingOn-site testing servicesEmployers
Occupational hygiene (e.g., ear-fit testing, exposure monitoring)Workplace exposure assessmentsIndustrial employers

Geotechnical Services (Queensland)

OfferingDescriptionTarget customer
Geotechnical investigation and studySite investigation for designCivil engineers, developers
Temporary works design and inspectionDesign and verification of temporary worksConstruction contractors
Construction-phase verificationCompliance testing during constructionPrincipal contractors, infrastructure owners
Earthworks supervisionLevel 1 / Level 2-type supervision of earthworksCivil contractors
Soil, concrete and aggregate testingMaterials testing laboratory servicesContractors, quarries
On-site mobile laboratory testingField labs deployed to projectsLarge civil projects

Software Services (Octfolio)

OfferingDescriptionTarget customerPricing model
Octfolio asbestos and hazmat platformSecure cloud platform for managing asbestos registers and hazardous-materials data; still marketed by ALS ERS in 2025–2026Large asset owners, government agencies, property portfoliosSubscription (specific pricing not publicly disclosed)
Field-management softwareMobile data capture for field consultantsConsultancies, internal teams—
Customised WHS compliance applicationsBespoke compliance toolsEnterprise clients—

Launch years and version histories for individual products are not publicly disclosed.

Financial Narrative

Coverage: HRL reported annual results through FY2021 (year ended 30 June 2021) and half-year results through 1H FY2022 (six months to 31 December 2021). It was compulsorily acquired before its FY2022 annual report would normally have been released to the market (late August 2022). No standalone HRL financials have been published since; HRL's post-acquisition results are consolidated within ALS Limited and not separately disclosed.

Income statement

Sources and notes: - FY2020 and FY2021 revenue, statutory EBITDA and statutory NPAT: Market Index financials page, compiled from HRL annual reports. Revenue FY2020 A$32,806,137; FY2021 A$34,612,000. Statutory EBITDA FY2020 A$8,579,110; FY2021 A$6,696,000. NPAT FY2020 −A$2,495,031; FY2021 A$1,312,000.

  • FY2021 underlying EBITDA (A$7.7m, +11%), underlying NPAT (A$3.2m, +27.7%) and revenue growth (+5.5%): HRL FY21 results release, via Kalkine.

  • FY2018 underlying EBITDA A$5.8m (+382%): HRL FY18 results (August 2018), via Strawman and Kalkine.

  • FY2020 underlying EBITDA and NPAT are derived by back-calculating from the disclosed FY2021 growth rates (7.7 / 1.11; 3.2 / 1.277).

  • FY2019 annual figures: not publicly disclosed in accessible sources. The AGM in November 2018 guided to a A$2.2–2.5m adverse EBITDA impact from the meth-testing downturn, about 30% of earnings (Livewire).

  • Dividends: no dividend payments by HRL are recorded in accessible sources; the dividend history is treated as nil or not publicly disclosed.

Half-year data points

Sources: 1H FY2020 from Stockhead (Feb 2020); 1H FY2021 from Taylor Collison (29 Jan 2021); 1H FY2022 from Craft (half-year to 31 Dec 2021). 1H FY2019 revenue derived from the disclosed 15% growth. The 1H FY2022 "gross profit" of A$14.7m on revenue of A$18.0m reflects a data-provider definition (likely revenue less consumables), not a conventional gross margin.

Margins

Computed from the figures in 6.1. FY2020 underlying margins use the derived underlying figures. The revenue CAGR over FY2020–FY2021 is 5.5%. The Analytica acquisition is documented as having roughly doubled group revenue in FY2018.

Balance sheet

Source: FY2020 and FY2021 net debt and FY2021 undrawn facilities from HRL FY21 results via Kalkine. Total assets, debt split, equity, goodwill and working capital are not publicly disclosed in accessible sources. Simply Wall St (2022) described the balance sheet as strong while also publishing an article saying HRL used debt "extensively". These conflicting automated assessments are noted; neither is relied on.

Cash flow

Source: FY2021 operating cash flow and FY2022 capex guidance (about A$4m) from HRL FY21 results via Kalkine. Earlier data point: in the September 2017 quarter, HRL generated A$0.405m of operating cash flow on A$5.4m of quarterly sales, with cash rising from A$0.728m to A$0.925m (Stockhead).

Commentary on trends, inflections and drivers

Inflection 1: the Analytica step-change (FY2018). Before November 2017, HRL was a hazmat consultancy generating about A$5–6m of quarterly sales (A$5.4m in the September 2017 quarter) with thin cash generation. The Analytica acquisition, funded by an equity raise at 8.5c, roughly doubled revenue and lifted underlying EBITDA by 382% to A$5.8m in FY2018. Centennial Asset Management, a cornerstone investor in the raise, stated that HRL was valued at about 6x FY2018E EV/EBITDA at the raise price, against domestic and global peers on 12–15x.

Inflection 2: the methamphetamine shock (FY2019). In 2018 the NZ meth-residue testing market collapsed after the Chief Science Advisor's report concluded that prevailing contamination thresholds were overly conservative. HRL quantified the FY2019 EBITDA impact at A$2.2–2.5m, about 30% of earnings. The stock had re-rated to about 11x FY2019 EV/EBITDA before the downgrade, which made the share-price reaction severe.

Inflection 3: recovery and the honey windfall (FY2020). FY2020 benefited from an exceptional NZ honey season despite COVID-19 disruption in April 2020. The 1H FY2020 loss alone was A$2.7m despite 15% revenue growth.

Inflection 4: normalisation and peak earnings (FY2021). Honey volumes normalised, but glyphosate and AFB testing, raw milk share gains and hazmat strength lifted underlying EBITDA 11% to A$7.7m. Net debt fell to A$0.4m and operating cash flow was A$5.5m. Final Analytica earn-out payments freed cash for growth, including the small Water Testing Hawke's Bay acquisition.

Inflection 5: softening and exit (1H FY2022). Revenue grew to A$18.0m, but the half produced a statutory net loss of A$0.73m and negative EBIT. Market commentators at the time noted that HRL's numbers had gone backward before ALS's approach. The undisturbed share price of 8.2c in June 2022 was roughly the level of the 2017 raise. That set up a takeover at a 95% premium which was still modest against HRL's peak underlying EBITDA: about A$82m equity value, roughly 10.7x FY2021 underlying EBITDA before adjusting for net debt.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentOperating entities / brandsProducts and servicesGeography

HAZMAT Services

Octief Pty Ltd (Australia); Precise Consulting (NZ)

Asbestos surveys and registers, hazmat management plans, air and dust monitoring, contamination assessments, soil sampling, workplace drug testing, on-site monitoring

Australia and NZ

Food and Environmental Laboratory Services

Analytica Laboratories (Hamilton, NZ); in-house asbestos labs; Water Testing Hawke's Bay (from 2021); equity interest in CAIQTest Pacific

Honey (mānuka authentication, glyphosate, AFB), milk and dairy, food origin, drugs-of-abuse, asbestos, environmental and water testing; lab R&D services

Predominantly NZ

Geotechnical Services

Queensland geotechnical testing operation

Geotechnical investigation, temporary works design and inspection, construction verification, earthworks supervision, soil/concrete/aggregate testing, mobile on-site labs

Queensland, Australia

Software Services

Octfolio

Cloud asbestos/hazmat information management, field-management software, WHS compliance applications

Australia and NZ

Segment Metric Details

Segment metricPeriodValueSource

Food & Laboratory segment revenue

1H FY2020

A$7.5m (about 46% of A$16.3m group revenue)

HRL 1H FY20 report, via Stockhead (Feb 2020)

HAZMAT segment profit

1H FY2020

Just over A$1m; only profitable segment that half

HRL 1H FY20 report, via Stockhead

Geotechnical segment

1H FY2020

Underperformed the prior-corresponding period; only division to go backwards

HRL 1H FY20 report, via Stockhead

Core laboratory testing revenue growth

1H FY2021

+13% year on year

Taylor Collison (29 Jan 2021)

Core laboratory EBITDA margin

1H FY2021

28%

Taylor Collison

Core laboratory share of group earnings

1H FY2021

About 80%

Taylor Collison

CAIQTest (Pacific) Limited revenue growth

FY2021

+36% vs prior year

HRL FY21 results, via Kalkine

Revenue drivers

FY2021

Strong growth in the food laboratory division; higher earnings from Analytica and HAZMAT

HRL FY21 results, via Kalkine

Segment revenue (AUD Mn)

FY2019

FY2020

FY2021

Group total

—32.834.6

Income Statement and Margin Analysis (%)

MetricFY2018FY2020FY2021

Revenue (AUD Mn)

—32.8134.61

Revenue growth YoY (%)

——5.5

EBITDA statutory (AUD Mn)

—8.586.70

EBITDA underlying (AUD Mn)

5.80—7.70

EBITDA underlying (derived, AUD Mn)

—6.94—

Net income statutory NPAT (AUD Mn)

—-2.501.31

Net income underlying NPAT (AUD Mn)

——3.20

Underlying NPAT (derived, AUD Mn)

—2.51—

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement and Margin Analysis (%) (Half-Yearly)

Metric1H FY2019 (derived)1H FY20201H FY20211H FY2022

Revenue (AUD Mn)

14.216.3—18.0

Revenue growth YoY (%)

—15——

EBITDA (AUD Mn)

——3.535—

EBITDA guidance range (AUD Mn)

——

3.2–3.5

—

Gross profit (AUD Mn)

———14.7

EBIT (AUD Mn)

———-0.569

Net profit after tax (AUD Mn)

—-2.7—-0.729

Cash at period end (AUD Mn)

———0.852

Margin Analysis (%)

MetricFY2020FY2021

Statutory EBITDA margin (%)

26.219.3

Underlying EBITDA margin (%)

21.222.2

Statutory net margin (%)

-7.63.8

Underlying net margin (%)

7.79.2

Key Financials

MetricFY2020FY2021FY2022

Net debt (AUD Mn)

1.10.4—

Undrawn debt facilities (AUD Mn)

—7.8—

Cash at 31 Dec 2021 (AUD Mn, 1H FY22)

——0.852

Cash Flow

MetricFY2021FY2022

Operating cash flow (AUD Mn)

5.5—

Capex guidance (AUD Mn)

—4.0

Financial Ratios (x) and Margin Analysis (%)

RatioFY2020FY2021Comment

Net debt / underlying EBITDA (x)

0.160.05

Computed; very low leverage

OCF / underlying EBITDA (%)

—71

Computed: 5.5 / 7.7

Geographic revenue (AUD Mn)

Geographic revenue (AUD Mn)FY2020FY2021

Total

32.8134.61

Segment Overview — Food and Environmental Laboratory

SegmentNew ZealandAustralia

Food and Environmental Laboratory

Dominant (Analytica, Hamilton; Water Testing Hawke's Bay)

Minor (in-house asbestos lab capability)

HAZMAT

Precise Consulting

Octief (Queensland-centred, including Yatala)

Geotechnical

—

Queensland civil and construction market

Software (Octfolio)

Some clients

Primary market

Share Price & Returns

Reference pointPrice (AUD)Date / source

2017 capital raise price

0.085

Oct–Nov 2017

Taylor Collison price target

0.18

29 Jan 2021

52-week low before the bid

0.075

Simply Wall St

Undisturbed close before the NBIO

0.082

27 Jun 2022

Offer price

0.16

30 Jun 2022

Intraday post-recommendation

0.165

30 Jun 2022

Last traded (approx.)

0.16

Aug 2022 (Craft cites 0.2 rounded)

Return metric (to delisting, %)

1 year

3 years

HRL total share price change

33.352.4

Valuation Multiples

MultipleHRL at 16cPeer reference

P/E (underlying NPAT, FY21)

about 25.7x

—

P/E (statutory NPAT, FY21)

about 62.7x

—

EV/EBITDA (underlying, FY21)

about 10.7x

Centennial cited peers at 12–15x EV/EBITDA (2017)

EV/Sales (FY21)

about 2.4x

—

Analyst Ratings & Targets

BrokerDateRatingTarget (AUD)

Taylor Collison

29 Jan 2021

Outperform

0.18

Consensus (Market Index / FN Arena)

Jun 2022

Strong Buy

—

“—” = not publicly disclosed.

Capital Markets

ItemDetail

Dividend history

No dividends identified; growth reinvestment and acquisition earn-outs prioritised

Buyback authorisations

None identified

Credit ratings (Moody's / S&P / Fitch)

Not rated

Debt maturity profile

Not publicly disclosed; FY21 undrawn facilities A$7.8m

Analyst Conclusions

Guidance and consensus

There is no management guidance or consensus for HRL Holdings, because it is no longer a reporting entity. The last forward-looking disclosures were FY2022 capex of about A$4m (August 2021) and the 2021 broker view (Taylor Collison) of about A$7.4m in FY2021 EBITDA, which HRL beat on an underlying basis (A$7.7m). The relevant outlook is now ALS's commentary on ANZ food and environmental testing demand, where ALS expects regulation and quality-assurance programmes to keep driving demand.

Bull-case arguments (for the HRL assets within ALS)

  1. Niche lab economics plus scale: Analytica's 28% EBITDA-margin specialist testing can grow faster inside ALS's ANZ network and client base than it could as a sub-scale independent.

  2. Digital moat: Octfolio, retained and promoted by ALS, gives ALS a sticky software layer in asbestos compliance and supports cross-selling of lab and consulting work.

  3. Regulatory tailwinds: food authenticity (mānuka), export certification (CAIQTest Pacific) and Australian asbestos WHS obligations are structural, compliance-driven demand sources.

Bear-case arguments

  1. Demand fragility: the 2018 meth-testing collapse (−A$2.2–2.5m EBITDA, about 30% of earnings) showed that regulatory reinterpretation can erase a testing market almost overnight.

  2. Seasonality and commodity exposure: honey volumes swing with harvests; FY2020's bumper season did not repeat in FY2021.

  3. Sub-scale legacy units: geotechnical and hazmat consulting showed lower and more cyclical returns, and the group's statutory earnings were repeatedly loss-making (FY2020, 1H FY2022).

Catalysts and monitorables (next 12 months)

MonitorableWhy it matters
ALS Life Sciences / Environmental segment commentary on ANZ food testingThe only remaining disclosure channel for former HRL businesses
NZ mānuka honey export volumes and MPI rule changesMain driver of Analytica's test volumes
NZ dairy and infant formula export trends to ChinaDriver of CAIQTest Pacific and dairy testing
Australian asbestos and silica regulatory changesDemand for ALS ERS (ex-Octief) and Octfolio
Further ALS brand rationalisation (Analytica, Precise)Signals depth of integration
ALS portfolio actions in ANZ (acquisitions or divestments)Could affect former HRL operations

Analyst verdict

HRL Holdings is best understood as a completed corporate life cycle rather than a live investment case. Over eight years, management turned a failed geothermal shell (Hot Rock Limited) into a profitable ANZ testing group. It did so by assembling Octief, Precise Consulting and, decisively, Analytica Laboratories. The Analytica deal, funded at 8.5c per share in 2017, created the group's one genuinely advantaged asset: a specialist NZ chemistry laboratory with leading positions in mānuka honey and dairy testing, generating about 80% of group earnings at margins near 28%.

The listed record was uneven. The NZ methamphetamine-testing collapse in 2018 cut about 30% of expected earnings and damaged credibility. Statutory results swung between profit and loss because of non-operating items. The geotechnical arm consistently underperformed. Yet underlying performance recovered to a peak in FY2021 (revenue A$34.6m, underlying EBITDA A$7.7m, near-zero net debt). That gave ALS a clean, low-risk asset to buy when HRL's share price slid back to 8.2c in mid-2022.

The 16c cash offer, a 95% premium, valued HRL at about A$82m, or roughly 10.7x FY2021 underlying EBITDA. Long-term holders from the 2017 raise roughly doubled their money. However, the price sat at or below the 12–15x EV/EBITDA range investors had cited for listed TIC peers, so ALS arguably bought a strategic niche at a sub-scale discount. The rapid passage to compulsory acquisition (12 August 2022) suggests shareholders broadly accepted that trade-off.

For analysts today, HRL's relevance is twofold. First, it is a case study in micro-cap TIC consolidation: niche labs with strong margins attract strategic buyers when public markets underprice them. Second, its assets continue within ALS, where their performance is no longer separately visible. Monitoring them now means reading ALS's ANZ food and environmental commentary rather than any HRL-specific disclosure.


Key sources referenced: ALS Limited news release "ALS expands food and environmental testing services with the acquisition of HRL Holdings" (6 Sep 2022); McCullough Robertson client result note on the HRL takeover (2022); Market Index HRL company and financials pages (FY2020–FY2021 data; delisting record); Market Index news on the ALS bid (30 Jun 2022); Motley Fool Australia HRL announcement feed (Jun 2022); HRL ASX announcements as indexed by StockLight (28 and 30 Jun 2022); Business News HRL profile (delisting date 26 Aug 2022); Simply Wall St HRL final snapshot; Craft HRL profile (1H FY2022 data); Kalkine FY2018 and FY2021 results summaries; Stockhead (Oct 2017; Feb 2020); Livewire Markets (Centennial Asset Management, 2018; NovaPort Capital, 30 Jul 2021); Taylor Collison research note summary (29 Jan 2021); Strawman member summaries of HRL investor presentations and announcements; ALS Environmental Risk Services webpage (2025–2026); ALS/Octief recruitment listing (Apr 2025).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleTenureNotes

Steven Dabelstein

Chief Executive Officer / Managing Director

—

Architect of the niche chemical testing strategy; described Analytica as a single-site lab offering capabilities HRL lacked (Stockhead, 2017)

Darren Anderson

Former Chair / Director

Guided the company from its earliest days; resigned from the board in Feb 2020 for health reasons

Long-standing founding-era director

Major Shareholders

HolderStakeDateSource

Perennial (Perennial Value Management / associated funds)

Sold to ALS; together with other acquisitions, gave ALS 19.99%

Jun 2022

Strawman summary of ALS/HRL announcement

ALS Limited (via Australian Laboratory Services Pty Ltd)

19.99% before the offer; 100% after compulsory acquisition

Jun–Aug 2022

Market Index; McCullough Robertson

Australian Ethical Investment

—2022

Strawman commentary

Centennial Asset Management

—

2017–2018

Livewire (Matthew Kidman)

NovaPort Capital

—2021

Livewire

Competitive Landscape

Competitors by Segment

SegmentCompetitorOwnership / listingPositioning vs HRL

Food and Environmental Lab (NZ)

Hill Laboratories

Private, NZ

NZ's largest independent lab; broad food, agri and environmental testing; principal NZ rival

Food and Environmental Lab (NZ/AU)

Eurofins (Eurofins NZ / ELS / Australia)

Euronext Paris listed (ERF)

Global scale food and environmental testing; strong in dairy

Food and Environmental Lab (NZ)

AsureQuality

NZ state-owned enterprise

Dominant in dairy and export assurance

Food and Environmental Lab (ANZ)

ALS Limited (pre-acquisition)

ASX: ALQ

Global environmental and food lab; became the acquirer

Food / commodities (ANZ)

SGS

SIX Swiss Exchange listed

Global TIC; food and agriculture

Food / commodities (ANZ)

Bureau Veritas

Euronext Paris listed

Global TIC; food, environmental and construction

Environmental lab (AU)

Envirolab Services

—

Major Australian environmental and asbestos lab

Hazmat consulting (AU)

Greencap

—

National hazmat and asbestos consultancy; direct Octief rival

Hazmat / OH consulting (ANZ)

WSP, Tetra Tech Coffey, and other engineering consultancies

Listed (TSX: WSP; NASDAQ: TTEK)

Large multidisciplinary consultancies with hazmat and geotechnical teams

Geotechnical / materials testing (QLD)

Regional NATA-accredited construction materials labs

Mostly private

Fragmented local competition

Hazmat software

Various asbestos register and EHS SaaS providers

Mostly private

Competing compliance software alternatives to Octfolio

Peer Comparison FY2021

MetricHRL Holdings (FY2021)Hill Laboratories

Revenue

A$34.6m

Not publicly disclosed (private)

Revenue growth

+5.5%—

EBITDA margin

22.2% underlying

—

“—” = not publicly disclosed.

Recent Developments

HRL ceased to exist as a reporting entity in August 2022. There is no HRL-specific corporate newsflow in the 18 months to October 2026.

Company Snapshot

$26M

Revenue

2006

Founded

Brisbane City, Australia

Headquarters

SWOT Analysis

Strengths

  • Advantaged niche laboratory asset: Core lab testing was about 80% of group earnings at 28% EBITDA margins (1H FY21, Taylor Collison)
  • Leadership in honey and dairy testing: ALS described Analytica as an industry leader in honey and dairy product testing (Sep 2022)
  • Low leverage: FY21 net debt A$0.4m; undrawn facilities A$7.8m
  • Cash generation: FY21 operating cash flow A$5.5m, about 71% of underlying EBITDA
  • Proven method innovation: Glyphosate and AFB testing sustained FY21 after the honey windfall normalised
  • Integrated digital layer: Octfolio retained and promoted by ALS after the acquisition
  • Guidance delivery: 1H FY21 EBITDA of A$3.535m at top of the A$3.2–3.5m range

Weaknesses

  • Sub-scale: About A$35m revenue vs multi-billion-dollar global peers; market cap just over A$55m in 2021
  • Single-site lab concentration: Analytica described by its CEO as a single-site lab (2017)
  • Laggard divisions: Geotechnical was the only division to decline in 1H FY20; it needed baseline contracts in 2021
  • Volatile statutory earnings: FY20 statutory NPAT −A$2.5m vs underlying profitability; 1H FY22 net loss A$0.73m
  • Earnings concentration: Hazmat was the only profitable segment at segment level in 1H FY20
  • Limited disclosure and coverage: Micro-cap with sparse broker coverage; Market Index noted no major broker coverage

Opportunities

  • Broader NZ milk testing: Taylor Collison estimated over A$2m of EBITDA potential from the about NZ$40m market
  • Transfer Analytica methods to Australia: Stated management intent (2017)
  • Geographic expansion to NSW/VIC: 2018 investor commentary
  • Bolt-on testing lines: Water Testing Hawke's Bay (2021)
  • Software monetisation: Octfolio flagged as an under-recognised opportunity (NovaPort, 2021)
  • Strategic sale to a consolidator: Realised: ALS paid a 95% premium (2022)

Threats

  • Regulatory demand shocks: NZ meth-testing collapse cut FY19 EBITDA by A$2.2–2.5m
  • Seasonal and crop risk: Honey volumes fell back sharply after the FY20 bumper season
  • Pandemic disruption: April 2020 NZ lockdown hit volumes
  • Global competitor scale: Eurofins, SGS, Bureau Veritas, ALS in ANZ
  • China export certification risk: CAIQTest Pacific dependence on China-bound trade flows
  • Construction cycle: Geotechnical exposure to Queensland civil activity

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
29 Jan 20211H FY21 EBITDA of A$3.535m reported, at top of A$3.2–3.5m guidanceRebuilt credibility
29 Jan 2021Taylor Collison retains Outperform, price target A$0.18; FY21 EBITDA forecast A$7.4mBroker support
1H FY2021Honey season start muted versus FY2020's bumper year; milk season normalSeasonal risk flagged
2021Water Testing Hawke's Bay acquiredBolt-on expansion
2021Final Analytica earn-out paymentsFCF freed for growth
2021Geotechnical arm secures baseline volume workLaggard segment stabilised
30 Jul 2021NovaPort Capital publicly backs HRL as a niche micro-cap (market cap just over A$55m)Institutional sponsorship
Aug 2021FY21 results: revenue A$34.6m (+5.5%), underlying EBITDA A$7.7m (+11%), underlying NPAT A$3.2m (+27.7%)Peak reported year
Aug 2021FY21 net debt A$0.4m; undrawn facilities A$7.8m; OCF A$5.5mBalance-sheet capacity for M&A
Aug 2021CAIQTest Pacific revenue +36% in FY21Export certification growth
Aug 2021FY22 capex guided at about A$4mInvestment cycle
Feb 20221H FY22: revenue A$18.0m, net loss A$0.73m, EBIT −A$0.57mEarnings deterioration
Early 2022Share price drifts toward 52-week low of about A$0.075Undervaluation set-up
30 May 2022ALS submits unsolicited NBIO at A$0.16 per shareChange-of-control process begins
7 Jun 2022HRL enters process deed with ALSDue diligence
Jun 2022ALS acquires Perennial's HRL stake, reaching 19.99%Pre-bid stake
27 Jun 2022Undisturbed closing price A$0.082Premium reference point
28 Jun 2022HRL responds to media speculation and discloses NBIO; shares post best day in over seven yearsMarket re-rating
28 Jun 2022ALS confirms it submitted a confidential non-binding proposalAcquirer confirmation
30 Jun 2022Bid Implementation Deed signed; board unanimously recommends 16c cash offer absent a superior proposalAgreed deal
30 Jun 2022HRL shares rise a further 10% to 16.5c (briefly above offer)Market tested for a counter-bid
Early Jul 2022Offer opens for a six-week periodAcceptance phase
Jul 2022Target's statement releasedFormal board recommendation
12 Aug 2022ALS relevant interest crosses compulsory-acquisition thresholdControl secured
Aug 2022ALS announces intention to compulsorily acquire the remaining HRL sharesMinority squeeze-out
26 Aug 2022HRL delisted from the ASXEnd of listed life
6 Sep 2022ALS announces the HRL acquisition and its brands (Analytica, Octief, Precise, Octfolio)Integration launch
Apr 2025Octief recruiting as "a member of ALS Global" in Yatala, QLDTransitional branding
2025–2026Octief rebranded to ALS Environmental Risk Services; Octfolio retainedFull brand integration

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

1 chart
Revenue by Region: Total rose from AUD 32.8 Mn in FY2020 to AUD 34.6 Mn in FY2021.
HRL Holdings Limited — Revenue by Region
Series (AUD Mn)FY2020FY2021
Total32.834.6

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.